Genfit SA

Genfit (GNFT) Stock

Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Genfit in June 2026.

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Stock Performance Snapshot

Above Average

Financial Health

Genfit is generating strong revenue and profits, indicating solid financial performance and cash generation.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring GNFT

Next-Gen Hepatic Therapeutics | Basket Overview

Next-Gen Hepatic Therapeutics | Basket Overview

The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.

Published: 24 May 2026

Explore Basket
MASH Drug Developers Could Attract M&A in 2025

MASH Drug Developers Could Attract M&A in 2025

Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.

Published: 19 September 2025

Explore Basket
Which Pharma Stocks Could Follow Wegovy's Success?

Which Pharma Stocks Could Follow Wegovy's Success?

Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.

Published: 21 August 2025

Explore Basket
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

Published: 19 August 2025

Explore Basket

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.